Team TNA: Tau-mediated neurodegeneration in Alzheimer’s disease
Alzheimer’s disease is the most common form of dementia worldwide, affecting millions of patients, with no therapeutic options available to date. While amyloid plaques have long been recognized as hallmarks of the disease, recent evidence suggests that abnormal post-translational modifications of the Tau protein are strongly involved in disease manifestation and progression. In Alzheimer’s disease, Tau is unable to perform its normal function in the stabilization of microtubules and is prone to hyperphosphorylation, aggregation and secretion.
We study the network of Tau post-translational modifications, interactions between different types of modifications, and their impact on Tau function and dysfunction in the disease state using materials obtained from sporadic Alzheimer’s disease patients as well as neurons derived from induced pluripotent stem cells. Analytical and biochemical approaches and screening methods are used to identify tractable therapeutic targets in Tau post-translational modification pathways that can serve as starting points for the development of therapeutic agents. We aim to define a characteristic signature of pathologic Tau post-translational modifications that will serve as a biomarker to support the diagnosis and monitor the progression of Alzheimer’s disease.
- Dr. Laura Gasparini
Scientific Director Translational Pharmacology, AbbVie (Industry mentor)
- Dr. Martin Fuhrmann
Group Leader, German Center for Neurodegenerative Diseases (DZNE), Bonn (Academic mentor)
Our Team Members
Dr. Dagmar Ehrnhöfer
- 2012–2015: Research Associate with Prof. Michael Hayden at the University of British Columbia, Vancouver, Canada
- 2007–2012: Postdoctoral researcher with Prof. Michael Hayden at the University of British Columbia, Vancouver, Canada
- 2001–2007: PhD with Prof. Erich Wanker at the Max-Delbrück-Centre for Molecular Medicine in Berlin, Germany
- Erwin Schrödinger Fellowship of the Austrian Science Fund (FWF)
- Fellowship of the Canadian Institutes for Health Research (CIHR)
Dr. Ebru Ercan
- 2011–2015: Postdoctoral researcher in neuroscience with Mustafa Sahin, MD, PhD, Dept. of Neurobiology at Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA. Neuron-oligodendrocyte interactions and myelination in autism spectrum disorders.
- 2006–2011: PhD in cell biology and biochemistry with Dr. Matthias Seedorf at the University of Heidelberg, Center for Molecular Biology, Heidelberg, Germany. Unconventional trafficking of proteins.
- 2004–2006: Master of Science in Molecular Bioengineering at the Technical University of Dresden. Thesis work at the Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Dr. David Schöndorf
Modeling neurodegenerative disorders using hiPSCs and gene editing techniques
- 2004 – 2009: Diploma (FH) Biochemistry, University of applied sciences Mannheim, Germany, Thesis under supervision of Dr. Wilfried Hornberger
- 2009 – 2011: Master of Science Neuroscience, University of Tübingen, Germany, Thesis under supervision of Prof. Thomas Gasser
- 2011 – 2017: PhD under supervision of Prof. Thomas Gasser, German center of Neurodegenerative Diseases (DZNE) in Tübingen, Germany
- 2008–2015: Generation, cultivation and differentiation of iPS cells (including lentiviral vector production/cloning) at the National Center for Tumor Diseases (NCT/DKFZ)
- 2005–2008: Training as biology laboratory assistant at Heidelberg University
2014–2015: Assistant at the Institute for Instrumental Analytics and Bioanalytics at the University of Applied Science in Mannheim, Germany
2013–2014: Master of Science in Biotechnology with focus on Biomedical Science and Technology, at the University of Applied Science in Mannheim, Germany
2008–2012: Bachelor of Science in Biotechnology at the University of Applied Science in Esslingen, Germany